The Motley Fool
04 Jul 2026, 08:02 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Biogen is acquiring RayThera for up to $1 billion to expand its anti-inflammatory and immune-mediated condition portfolio. — A significant investment in a new pipeline targets long-term growth and diversification away from declining MS revenues.
+0.40Biogen's growth products, including Leqembi, Skyclarys, and Zurzuvae, saw a 12% increase in sales to $850 million in the first quarter. — Double- and triple-digit growth in new neurology drugs suggests the company's turnaround strategy is successfully offsetting patent losses.
+0.30Biogen recently completed the acquisition of Apellis Pharmaceuticals, adding two commercialized drugs with $689 million in last year's sales. — Immediate revenue contribution from established assets in the immunology and rare disease sectors reduces risk.
+0.20Continue reading
6 related stories
Top 1 mover · tap to explore
Biogen's core Multiple Sclerosis (MS) franchise continues to decline, with Tecfidera sales dropping from $4.4 billion in 2019 to $1.4 billion in 2022. — The loss of exclusivity for blockbuster drugs creates a persistent revenue headwind that the company must outpace.
-0.20Which stocks this story touches
The company is successfully executing a turnaround plan, stabilizing its business, and expanding its pipeline through strategic acquisitions.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
2h ago
